Blood Animation, Blood Illustrations

HemoBioTech Announces New Patent For Treating Acute Blood Loss
HemoBioTech (Pink Sheets:HMBT) announced the issuance of a new patent US 7,759,306 B2, "Methods of Treating Acute Blood Loss." HemoBioTech has an exclusive worldwide license from Texas Tech University to commercialize the technology. The new patent continues to May 16, 2026. The new patent involves HemoTech which induces the production of new red blood cells in the body...

Synta Announces STA-9090 Results Published In Journal "Blood" Demonstrating Potent In Vitro And In Vivo Activity In AML
Synta Pharmaceuticals Corp...

Hospira Begins Phase I U.S. Clinical Trial Of Biosimilar Erythropoietin In Renal Patients
Hospira, Inc. (NYSE: HSP), the world leader in generic injectable pharmaceuticals, announced the start of a U.S. Phase I clinical trial of its biosimilar erythropoietin (EPO) in patients with renal (kidney) dysfunction who have anemia, an important step on the road toward introducing a biosimilar product in the United States...

Medicare To Bundle Payments For End-Stage Renal Care, Reward Quality
Modern Healthcare: Medicare payment for end-stage renal disease care may soon be tied to performance and quality measures if a new proposed rule issued by the Centers for Medicare and Medicaid Services is finalized...

NICE Recommends Leukaemia Drug For NHS Use
Rituximab (MabThera, Roche Products) will now be routinely available to certain NHS patients with chronic lymphocytic leukaemia, thanks to final guidance published today (28 July). The NHS has three months to begin implementing this new guidance...

MabCure, Inc. Announces Positive Results For New Ovarian Cancer Diagnostic Blood Test
Biotechnology company MabCure, Inc. (OTC Bulletin Board: MBCI) announced that a confirmatory study demonstrated the company's proprietary monoclonal antibodies (MAbs) successfully identified ovarian cancer in blood (94 percent accuracy) and with no false positives or cross-reactions with benign ovarian tumors or healthy blood...

CMS Approves Clinical Study Of Genetic Test To Predict Patient Response To Leading Anticoagulant Drug Warfarin
Iverson Genetic Diagnostics announced the company has received approval from CMS to conduct a WARFARIN Clinical Study. The two-year study will assess the impact of genetic information in calculating doses and the changes in the rate of adverse events when initiating Warfarin drug therapy. These changes will be compared against doses initiated without genetic data...

What Is Blood? What Does Blood Do?
Blood is a combination of plasma (watery liquid) and cells that float in it. It is a specialized bodily fluid that supplies essentials substances and nutrients, such as sugar, oxygen, and hormones to our cells, and carries waste away from those cells, this waste is eventually flushed out of the body in urine, feces, sweat, and lungs (carbon dioxide). Blood also contains clotting agents...

Roche Receives FDA Clearance For CoaguChek XS Pro System With Bar Code Reader For PT/INR Testing At The Point Of Care
Roche Diagnostics announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the CoaguChek® XS Pro system, a new point-of-care anticoagulation monitor with a built-in bar code reader that can automatically scan and capture operator and patient identification information...

First Nations People On Peritoneal Dialysis At Greater Risk Of Infection And Death
First Nations people in Canada on peritoneal dialysis are at increased risk of peritonitis and death, irrespective of whether they live in a rural or urban location, found a study published in CMAJ (Canadian Medical Association Journal)...

Rare And Common Genetic Variations Responsible For High Triglyceride Levels In Blood
It can make blood look like cream of tomato soup. Patients with high levels of triglycerides in their blood, a disease called hypertriglyceridemia (HTG) face an increased risk for heart disease and stroke. HTG affects one in 20 people in North America and is also associated with obesity, diabetes and pancreatitis...

Sickle Cell Treatment Developed At LA BioMed Enters Phase 3 Clinical Trial
An experimental treatment for sickle cell disease developed at the Los Angeles Biomedical Research Institute (LA BioMed) has entered Phase 3 clinical trials, David I. Meyer, PhD, LA BioMed president and CEO have announced . Researchers throughout the U.S...

FDA Approves First Generic Enoxaparin Sodium Injection To Prevent DVT
The U.S. Food and Drug Administration approved the first generic version of Lovenox (enoxaparin sodium injection), an anti-coagulant drug used to prevent deep vein thrombosis (DVT), a potentially deadly blood clotting condition. Approved for use in 1993, Lovenox is made from heparin, a blood-thinning drug whose active ingredient is a naturally-derived complex mixture of sugar molecules...

CytRx's Tamibarotene Eradicates Cancer In Advanced Acute Promyelocytic Leukemia After Failure Of Other Therapies
CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical company specializing in oncology, announced that a 44-year-old female patient with advanced acute promyelocytic leukemia (APL) achieved molecular complete remission with no evidence of disease in the blood cells and/or bone marrow following treatment with CytRx's oncology drug candidate tamibarotene...

FDA Approves First Generic Blood Thinner Enoxaparin Sodium Injection (Lovenox)
The U.S. FDA (Food and Drug Administration) announced it has approved the 1st generic version of enoxaparin sodium injection (Lovenox), an anti-coagulant (blood thinner) used for the prevention of DVT (deep vein thrombosis), as well as some other therapies. Lovenox is made from heparin and was approved for use in the USA in 1993...